Primary and secondary outcomes
| Increased BP | Stable BP | P value | |
| % Survival >1 month | 99 (192/193) | 88 (132/150) | <0.001 |
| % Survival >6 month | 96 (152/159) | 79 (92/116) | <0.001 |
| % Survival >1 year | 89 (116/130) | 67 (65/97) | <0.001 |
| % Survival >2 year | 72 (59/82) | 46 (30/65) | 0.002 |
| Periprocedural major vascular | 14 (7) | 15 (10) | 0.435 |
| Periprocedural minor vascular | 15 (8) | 15 (10) | 0.564 |
| Post-TAVR PPM implantation | 18 (9) | 10 (7) | 0.430 |
| Inhospital | |||
| CV mortality | 1 (1) | 18 (12) | <0.001 |
| MI | 1 (1) | 1 (1) | 1.000 |
| Stroke/TIA | 3 (2) | 6 (4) | 0.187 |
| HF exacerbation | 36 (19) | 37 (25) | 0.186 |
| Discharge to 30 days | |||
| MACCE | 36 (19) | 21 (16) | 0.554 |
| CV mortality | 0 (0) | 1 (1) | 0.410 |
| Myocardial Infraction | 2 (1) | 2 (2) | 1.000 |
| Stroke/TIA | 2 (1) | 1 (1) | 1.000 |
| HF exacerbation | 32 (17) | 19 (14) | 0.642 |
| Rehospitalisation For any reason | 35 (18) | 21 (16) | 0.654 |
| 30 days–6 months | |||
| MACCE | 45 (29) | 24 (25) | 0.472 |
| CV mortality | 4 (3) | 1 (1) | 0.652 |
| MI | 1 (1) | 3 (3) | 0.160 |
| Stroke/TIA | 4(3) | 2 (2) | 1.000 |
| HF exacerbation | 30 (19) | 8 (8) | 0.018 |
| Rehospitalisation for any reason | 44 (28) | 19 (20) | 0.137 |
| 6 months–1 year | |||
| MACCE | 39 (34) | 17 (25) | 0.189 |
| CV mortality | 3 (3) | 1 (1) | 1.000 |
| MI | 3 (3) | 1 (1) | 1.000 |
| Stroke/TIA | 2 (2) | 1 (1) | 1.000 |
| HF exacerbation | 33 (29) | 2 (3) | <0.001 |
| Rehospitalisation for any reason | 37 (32) | 14 (20) | 0.090 |
Values are % (n).
BP, blood pressure; CV, cardiovascular; HF, heart failure; MACCE, major adverse cardiovascular and cerebrovascular events, defined as death from any cause, MI, rehospitalisation and stroke; MI, myocardial infarction; PPM, permanent pacemaker; TAVR, transcatheter aortic valve replacement; TIA, transient ischaemic attack.